Who is sponsoring NCT00294567?

NCT00294567 is sponsored by Juntendo University.

What drugs are being tested in NCT00294567?

Interventions in NCT00294567: Calcium channel blockers (amlodipine, azelnidipine).

What condition does NCT00294567 study?

NCT00294567 studies Hypertension, Coronary Atherosclerosis.

Is NCT00294567 still recruiting?

NCT00294567 is currently completed. Last updated 12 May 2021.

Last reviewed 2021-05-12 · How we verify

NCT00294567

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azelnidipine and Amlodipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Junten Medical University (ALPS-J)

Completed Phase 4 Last updated 12 May 2021

What this trial tests

Phase 4 trial testing Calcium channel blockers (amlodipine, azelnidipine) in Hypertension in 199 participants. Completed in 1 January 2011.

Timeline

1 December 2005

Primary endpoint
1 May 2009

1 January 2011

Quick facts

Lead sponsor	Juntendo University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	199
Start date	1 December 2005
Primary completion	1 May 2009
Estimated completion	1 January 2011
Sites	1 location across Japan

Drugs / interventions tested

Calcium channel blockers (amlodipine, azelnidipine) — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →
Coronary Atherosclerosis — all drugs for Coronary Atherosclerosis →

Sponsor

Juntendo University

Who can join

Adults 20 to 79, any sex, with Hypertension or Coronary Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent change in plaque volume from the baseline value. (IVUS) Percent change in plaque volume = (plaque volume after 48 weeks of drug administration - baseline plaque volume) / baseline plaque volume
Time frame: 48Weeks

Sponsor's own description

In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Juntendo University trials

Trials by the same sponsor.

NCT05392764 — Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure · Phase 3 · recruiting
NCT04950842 — Induction of Transplant Tolerance in LDLT Via iTS · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00294567 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juntendo University
Last refreshed: 12 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00294567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing